PLEASANTON, Calif., May 25, 2021 /PRNewswire/ — Noctrix Health, Inc. today announced that the first patient has been enrolled in a multi-center, randomized controlled clinical trial. The RESTFUL Study (ClinicalTrials.gov Identifier: NCT04874155) is a first of its kind two-phase, randomized, double-blind, sham-controlled clinical trial to evaluate the Company’s proprietary wearable NTX100 Neuromodulation System in patients with…

Read More

SAN FRANCISCO, June 2, 2020 /PRNewswire/ — Noctrix Health, Inc., a privately held medical device company announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapydesigned for the treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS) who are refractory to medications. RLS is…

Read More

SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ — Noctrix Health, Inc., a private medical device company, today announced it has completed a Series B financing of $17 million. The financing was co-led by Treo Ventures and OrbiMed, with participation from LivaNova PLC (NASDAQ: LIVN) and other insiders. As part of this financing, Tracy Pappas (Treo Ventures) and…

Read More